drugset / Trial / NCT00807937

Proof of Concept in Patients With Generalized Anxiety Disorder (GAD)AZD7325

NCT00807937

Phase 2 Completed 369 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this research study is to determine whether AstraZeneca's drug AZD7325 is safe and effective in the treatment of generalized anxiety disorder.

Timeline

Start
2008-12
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD7325 Small molecule 5 mg Oral
Subject AZD7325 Small molecule 15 mg Oral
Comparator Lorazepam Small molecule 2 mg Oral